2020 CSCO 非小细胞肺癌诊疗指南

2020-05-20 中国抗癌协会临床肿瘤学协作专业委员会 CSCO

基于循证医学证据和精准医学基本原则制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会

中文标题:

2020 CSCO 非小细胞肺癌诊疗指南

发布日期:

2020-05-20

简要介绍:

基于循证医学证据和精准医学基本原则制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会
(CSCO)的基本任务之一。近年来,国际上指南的制定出现了一个新的趋向,即要考虑诊疗手段新颖性,还
需要兼顾资源可及性,这尤其适合我国这一发展中国家。中国是一个幅员辽阔但地区发展不平衡的国家,因此,
CSCO 非小细胞肺癌指南充分考虑药物和治疗措施的可及性、肿瘤治疗成本效益比及地区发展不平衡这三个方
面,对于每一个临床诊疗问题的推荐级别,分为Ⅰ级推荐、Ⅱ级推荐和Ⅲ级推荐三个层次。Ⅰ级推荐属于可及
性好的普适性诊治措施(如具有明确适应证),肿瘤治疗价值相对稳定,或为国家医保所收录;Ⅱ级推荐多属
于国际或国内已有随机对照的多中心研究提供的高级别证据,但是可及性欠佳或者效价比低,已超出平民经济
承受能力的药物或治疗措施;Ⅲ级推荐为正在探索的诊治手段,虽然缺乏强有力的循证医学证据,但是专家组
具有一致共识的推荐;考虑到国际肺癌诊疗发展的不平衡,对于部分欧美已批准上市并获得肺癌适应证,但我
国尚未上市的方案,经过讨论后本指南也作为Ⅲ级推荐。 CSCO 非小细胞肺癌指南工作委员会期待大家的反
馈,并将定期更新,保持 CSCO 指南的时效性。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020+CSCO+非小细胞肺癌诊疗指南.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8ad4b1c0020ae3ae, title=2020 CSCO 非小细胞肺癌诊疗指南, enTitle=, guiderFrom=CSCO, authorId=0, author=, summary=基于循证医学证据和精准医学基本原则制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会, cover=https://img.medsci.cn/2021131/1612084044263_2020535.jpg, journalId=0, articlesId=null, associationId=19, associationName=中国抗癌协会临床肿瘤学协作专业委员会, associationIntro=中国抗癌协会临床肿瘤学协作专业委员会(简称CSCO)是由临床肿瘤专业工作者和有关的企事业单位自愿组成的全国性专业学术团体。本着&ldquo;团结、协作、务实&rdquo;的根本宗旨和&ldquo;服务、协调、引导&rdquo;的工作理念,自成立以来,CSCO广泛地团结和组织全国临床肿瘤工作者和相关企事业单位,致力于推动部门之间、学科之间的密切合作,积极开展临床肿瘤学继续教育,广泛宣传GCP和循证医学,加强中西医结合,提倡以化疗、放疗、手术、生物治疗和中医药治疗等多种手段有计划、合理的综合治疗,大力推动肿瘤诊断治疗的规范化、标准化和专业化进程,促进国际国内学术交流和多中心协作研究,为提高我国临床肿瘤学界的整体水平,建立和弘扬有中华民族特色的临床肿瘤学事业而努力奋斗。, copyright=0, guiderPublishedTime=Wed May 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>基于循证医学证据和精准医学基本原则制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会<br />(CSCO)的基本任务之一。近年来,国际上指南的制定出现了一个新的趋向,即要考虑诊疗手段新颖性,还<br />需要兼顾资源可及性,这尤其适合我国这一发展中国家。中国是一个幅员辽阔但地区发展不平衡的国家,因此,<br />CSCO 非小细胞肺癌指南充分考虑药物和治疗措施的可及性、肿瘤治疗成本效益比及地区发展不平衡这三个方<br />面,对于每一个临床诊疗问题的推荐级别,分为Ⅰ级推荐、Ⅱ级推荐和Ⅲ级推荐三个层次。Ⅰ级推荐属于可及<br />性好的普适性诊治措施(如具有明确适应证),肿瘤治疗价值相对稳定,或为国家医保所收录;Ⅱ级推荐多属<br />于国际或国内已有随机对照的多中心研究提供的高级别证据,但是可及性欠佳或者效价比低,已超出平民经济<br />承受能力的药物或治疗措施;Ⅲ级推荐为正在探索的诊治手段,虽然缺乏强有力的循证医学证据,但是专家组<br />具有一致共识的推荐;考虑到国际肺癌诊疗发展的不平衡,对于部分欧美已批准上市并获得肺癌适应证,但我<br />国尚未上市的方案,经过讨论后本指南也作为Ⅲ级推荐。 CSCO 非小细胞肺癌指南工作委员会期待大家的反<br />馈,并将定期更新,保持 CSCO 指南的时效性。</p>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=15, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11837, appHits=1595, showAppHits=0, pcHits=2951, showPcHits=10242, likes=17, shares=139, comments=110, approvalStatus=1, publishedTime=Sun Jan 31 17:51:13 CST 2021, publishedTimeString=2020-05-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Jan 31 17:07:27 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 07:21:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020+CSCO+非小细胞肺癌诊疗指南.pdf)])
2020+CSCO+非小细胞肺癌诊疗指南.pdf
下载请点击:
评论区 (77)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1195371, encodeId=27e311953e16d, content=学习一下,倍儿香, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220221/b5f4465c02b84e6a9b441c91bffecc04/3a41d0851d584ea38af5c0d6da9bdf0e.jpg, createdBy=e7a95686665, createdName=ms2000002021385777, createdTime=Sun Feb 20 15:57:18 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192108, encodeId=56861192108fd, content=2021的有没有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Thu Feb 10 23:31:15 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187122, encodeId=c09c118e1221d, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220406/3b7a0097d1734882a9d49e4ae21b3eac/d2335d2d39cd4ee0b008a7edef49050b.jpg, createdBy=86032306225, createdName=sylphe, createdTime=Sat Jan 22 09:55:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082415, encodeId=046c10824157d, content=学习好资料!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:52:36 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074932, encodeId=084410e4932e0, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/d776fb0de4964edb8c8a81cffc82be49/f82fb8b5fd4b491796821dbf06ac64d5.jpg, createdBy=7fc12544791, createdName=1252be95m13暂无昵称, createdTime=Mon Nov 29 06:37:43 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2022-02-20 ms2000002021385777

    学习一下,倍儿香

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1195371, encodeId=27e311953e16d, content=学习一下,倍儿香, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220221/b5f4465c02b84e6a9b441c91bffecc04/3a41d0851d584ea38af5c0d6da9bdf0e.jpg, createdBy=e7a95686665, createdName=ms2000002021385777, createdTime=Sun Feb 20 15:57:18 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192108, encodeId=56861192108fd, content=2021的有没有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Thu Feb 10 23:31:15 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187122, encodeId=c09c118e1221d, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220406/3b7a0097d1734882a9d49e4ae21b3eac/d2335d2d39cd4ee0b008a7edef49050b.jpg, createdBy=86032306225, createdName=sylphe, createdTime=Sat Jan 22 09:55:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082415, encodeId=046c10824157d, content=学习好资料!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:52:36 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074932, encodeId=084410e4932e0, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/d776fb0de4964edb8c8a81cffc82be49/f82fb8b5fd4b491796821dbf06ac64d5.jpg, createdBy=7fc12544791, createdName=1252be95m13暂无昵称, createdTime=Mon Nov 29 06:37:43 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2022-02-10 恒心

    2021的有没有

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1195371, encodeId=27e311953e16d, content=学习一下,倍儿香, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220221/b5f4465c02b84e6a9b441c91bffecc04/3a41d0851d584ea38af5c0d6da9bdf0e.jpg, createdBy=e7a95686665, createdName=ms2000002021385777, createdTime=Sun Feb 20 15:57:18 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192108, encodeId=56861192108fd, content=2021的有没有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Thu Feb 10 23:31:15 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187122, encodeId=c09c118e1221d, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220406/3b7a0097d1734882a9d49e4ae21b3eac/d2335d2d39cd4ee0b008a7edef49050b.jpg, createdBy=86032306225, createdName=sylphe, createdTime=Sat Jan 22 09:55:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082415, encodeId=046c10824157d, content=学习好资料!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:52:36 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074932, encodeId=084410e4932e0, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/d776fb0de4964edb8c8a81cffc82be49/f82fb8b5fd4b491796821dbf06ac64d5.jpg, createdBy=7fc12544791, createdName=1252be95m13暂无昵称, createdTime=Mon Nov 29 06:37:43 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2022-01-22 sylphe

    太棒了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1195371, encodeId=27e311953e16d, content=学习一下,倍儿香, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220221/b5f4465c02b84e6a9b441c91bffecc04/3a41d0851d584ea38af5c0d6da9bdf0e.jpg, createdBy=e7a95686665, createdName=ms2000002021385777, createdTime=Sun Feb 20 15:57:18 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192108, encodeId=56861192108fd, content=2021的有没有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Thu Feb 10 23:31:15 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187122, encodeId=c09c118e1221d, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220406/3b7a0097d1734882a9d49e4ae21b3eac/d2335d2d39cd4ee0b008a7edef49050b.jpg, createdBy=86032306225, createdName=sylphe, createdTime=Sat Jan 22 09:55:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082415, encodeId=046c10824157d, content=学习好资料!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:52:36 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074932, encodeId=084410e4932e0, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/d776fb0de4964edb8c8a81cffc82be49/f82fb8b5fd4b491796821dbf06ac64d5.jpg, createdBy=7fc12544791, createdName=1252be95m13暂无昵称, createdTime=Mon Nov 29 06:37:43 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-12-21 龙珠

    学习好资料!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1195371, encodeId=27e311953e16d, content=学习一下,倍儿香, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220221/b5f4465c02b84e6a9b441c91bffecc04/3a41d0851d584ea38af5c0d6da9bdf0e.jpg, createdBy=e7a95686665, createdName=ms2000002021385777, createdTime=Sun Feb 20 15:57:18 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192108, encodeId=56861192108fd, content=2021的有没有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Thu Feb 10 23:31:15 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187122, encodeId=c09c118e1221d, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220406/3b7a0097d1734882a9d49e4ae21b3eac/d2335d2d39cd4ee0b008a7edef49050b.jpg, createdBy=86032306225, createdName=sylphe, createdTime=Sat Jan 22 09:55:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082415, encodeId=046c10824157d, content=学习好资料!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:52:36 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074932, encodeId=084410e4932e0, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/d776fb0de4964edb8c8a81cffc82be49/f82fb8b5fd4b491796821dbf06ac64d5.jpg, createdBy=7fc12544791, createdName=1252be95m13暂无昵称, createdTime=Mon Nov 29 06:37:43 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
    2021-11-29 1252be95m13暂无昵称

    很好

    0

拓展阅读

ASCO指南:IV期非小细胞肺癌的维持治疗(2009)

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2009-12-20

2010CCO 晚期非小细胞肺癌一线全身化疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

2010ESMO临床实践指南:早期和局部晚期(非转移性)非小细胞肺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2010ESMO临床实践指南:转移性非小细胞肺癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01